Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. The study published in the Journal of Experimental Medicine (JEM), shows that genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of NEPC tumors in mice, and lays the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans.
Continue Reading this article here
